No Data
Eterna Therapeutics Launches Research to Evaluate Its Lead Induced Mesenchymal Stem Cell Therapy Candidate's (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models
Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program
Express News | Eterna Therapeutics Announces up to $1 Million Stock Repurchase Program
12 Health Care Stocks Moving In Monday's Pre-Market Session
Why Tesla Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Eterna Therapeutics Regains Compliance With NASDAQ for Continued Listing
No Data